➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: August 10, 2020

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Prometrium patents expire, and what generic alternatives are available?

Prometrium is a drug marketed by Virtus Pharms and is included in one NDA.

The generic ingredient in PROMETRIUM is progesterone. There are fifty-seven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the progesterone profile page.

US ANDA Litigation and Generic Entry Outlook for Prometrium

A generic version of PROMETRIUM was approved as progesterone by FRESENIUS KABI USA on April 25th, 2001.

  Start Trial

Drug patent expirations by year for PROMETRIUM
Drug Prices for PROMETRIUM

See drug prices for PROMETRIUM

Recent Clinical Trials for PROMETRIUM

Identify potential brand extensions & 505(b)(2) entrants

National Institute of Mental Health (NIMH)Phase 2
University of North Carolina, Chapel HillPhase 2
University of California, DavisPhase 1/Phase 2

See all PROMETRIUM clinical trials

Pharmacology for PROMETRIUM
Drug ClassProgesterone

US Patents and Regulatory Information for PROMETRIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Virtus Pharms PROMETRIUM progesterone CAPSULE;ORAL 019781-001 May 14, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
Virtus Pharms PROMETRIUM progesterone CAPSULE;ORAL 019781-002 Oct 15, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Virtus Pharms PROMETRIUM progesterone CAPSULE;ORAL 019781-003 Oct 15, 1999 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.